Ocugen is helping Bharat Biotech develop the vaccine candidate for the U.S. market. Covaxin is a highly purified and inactivated vaccine manufactured using a Vero cell manufacturing platform. Covaxin has demonstrated 78% efficacy against COVID-19, according to recently published interim phase III clinical results.

In a number of studies, researchers from the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) found that Covaxin is effective not only against the Brazil variant but also against the U.K. and Indian variants, according to Ocugen. The vaccine is being developed in a collaboration between Bharat Biotech and ICMR-NIV.

Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine...

How the South African SARS-CoV-2 variant evades antibodies
Computer modeling has demonstrated that one of the three mutations of the South African SARS-CoV-2 variant reduces its ability to bind to human cells....

Bavarian Nordic posts positive preclinical data for its COVID-19 vaccine
Bavarian Nordic reported that additional preclinical data confirms its COVID-19 vaccine candidate can induce neutralizing antibodies against SARS-CoV-2...

VBI touts positive preclinical COVID-19 vaccine data
Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle technology from VBI Vaccines (VBI).

It's time to enlist research labs in the COVID-19 fight
Careful incorporation of research laboratories into the COVID-19 testing effort could increase capacity in the U.S. and globally, writes molecular diagnostics...